ANZCTR search results

Double-blind randomized sham-controlled trial. Transcutaneous auricular vagal nerve stimulation (taVNS) is a safe, non-invasive neuromodulation technique that delivers electrical stimulation to the auricular branch of the vagus nerve via electrodes placed on the tragus of the ear. Vagal nerve stimulation (VNS) is known to provoke brain arousal via release of noradrenaline and acetylcholine in cortex. Given there are no treatments for delirium, taVNS represents a paradigm shift in the approach, and would avoid polypharmacy effects that often contribute to treatment complexities in acutely ill older adults.

This study is testing whether intravenous (IV) lignocaine, a medicine normally used as a local anaesthetic, can help relieve severe migraine attacks in the Emergency Department. Adults who come to hospital with migraine that has not improved with their usual treatments may be invited to take part. Participants will receive lignocaine through a drip over one hour, together with a routine medicine called dexamethasone, and their pain and side effects will be closely monitored. If the migraine does not improve after two hours, standard treatments will still be provided. The aim of this pilot study is to see if IV lignocaine is safe, practical to use, and shows early signs of effectiveness, so that larger studies can be planned.

This study aims to co-design and test a telehealth-delivered, stoma-specific exercise and physical activity program to ensure it meets the needs of people living with a stoma. Who is it for? You may be eligible for this study if you are: A male or female age 18 or older, who has received a stoma as a result of Inflammatory Bowel Disease (IBD) or cancer in the five years prior to enrolment. A stoma is either permanent or long-term. Have access to the internet and own, or have access to, a computer or tablet device. or, A health professional working with people who have a stoma Study details: Participants will be involved in different ways depending on their group: Consumers with lived experience of a stoma will help co-adapt and refine the FOXTROT X exercise intervention through an interactive series of workshop sessions. Healthcare professionals will also assist in co-adapting the FOXTROT X exercise intervention during a collaborative workshop with consumers. People with a stoma due to cancer will test the 12-week exercise program (delivered via telehealth), followed by a 12-week maintenance period. Participants will also complete quality of life assessments and may undergo simple health checks, such as surveys. There is no randomisation — all eligible participants will receive the intervention or be involved in its design and evaluation. It is hoped that findings from this study will enhance physical activity and quality of life in the stoma community.

Stroke rehabilitation remains limited in effective solutions for upper-limb recovery. Two key approaches include providing high doses of intensive training and leveraging strategies that harness neuroplasticity. Aerobic exercise has gained increasing attention for its ability to enhance neuroplasticity and accelerate motor learning. Evidence suggests that moderate and high-intensity exercise can increase excitability within the primary motor cortex in the chronic phases of stroke. Such evidence warrants further investigations into whether such aerobic exercise paradigms may increase the brain's responsiveness to rehabilitation. Therefore, this study seeks to investigate the feasibility of whether high-intensity interval training or moderate-intensity training on a recumbent exercise bike, 30 minutes before therapy, 3 days a week, over a 5-week intensive rehabilitation program, may help prime the brain for rehabilitation and further improve clinical outcomes in chronic stroke.

This intervention is a novel and time-efficient program designed to enhance students' mental health and wellbeing. The intervention integrates school-based physical activity breaks with Cognitive Behavioural Therapy (CBT) techniques. Our project will evaluate the feasibility of this intervention among senior secondary school students.

This study aims to find out which simulation training method helps nurses perform better during a simulated resuscitation. It compares two approaches: Rapid Cycle Deliberate Practice (RCDP), which involves short, repeated practice with immediate feedback, and Traditional Immersive Simulation (TIS), which uses longer, more realistic scenarios and formal debriefing feedback. The main goal is to see which method results in better resuscitation performance such as faster delivery of defibrillation and higher quality chest compressions. We hypothesize that nurses trained with RCDP will perform this critical step more quickly than those trained with TIS.

This study aims to evaluate a novel mediated reality intervention for clinical use in those with knee osteoarthritis. Previous work has shown that mediated reality can be used to deliver body re-sizing illusions that reduce knee osteoarthritis symptoms. Recently we have worked with end-users to develop a clinic-ready version of this technology. The overarching aim of this project to test the clinic-ready version of this technology and evaluate its feasibility, acceptability, and preliminary efficacy in those with knee osteoarthritis.

The drug colchicine has been shown to be effective for cardiovascular disease prevention in the general population but is there is limited data available on colchicine in patients who are receiving haemodialysis for end-stage kidney disease. This project will aim to study the drug colchicine in patients who are receiving haemodialysis by examining for accumulation of colchicine, adverse effects of colchicine and effectiveness at colchicine at limiting inflammation markers. Three doses of colchicine will be used: 0.25mg three times weekly, 0.5mg three times weekly and 0.5mg daily. Participants will receive each dose of colchicine for 2 weeks sequentially. Findings from this study will provide a basis for larger clinical trials using colchicine in patients on haemodialysis.

Brief Summary: This study investigates the relationship between the immune microenvironment and Minimal Residual Disease (MRD) response in patients with amyloid light chain (AL) Amyloidosis treated with standard-of-care Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCD). It aims to improve MRD monitoring through novel flow cytometry and mass spectrometry techniques in peripheral blood, and to correlate these with bone marrow MRD assessed via EuroFlow. Aim: Unmet Need While most patients respond well to D-VCD, a subset experiences suboptimal outcomes. There is a need to identify these patients early and refine MRD detection methods to guide treatment decisions more effectively. Who is it for: Adults diagnosed with AL amyloidosis who are receiving first-line treatment with D-VCD, are eligible for MRD assessment and sample collection, and consented onto the Myeloma and Related Disease Registry (MRDR). Study Design: Prospective, observational correlative science study. Peripheral blood samples will be collected at baseline and at the start of the 6 treatment cycles, with bone marrow and blood collected post-induction and prior to maintenance therapy. MRD will be assessed using EuroFlow in bone marrow and novel flow cytometry and mass spectrometry in peripheral blood. It is hoped this study will: Identify immunological markers associated with MRD clearance. Improve MRD detection sensitivity and concordance between bone marrow and peripheral blood. Enable earlier identification of patients at risk of poor outcomes. Support MRD-guided treatment strategies in AL amyloidosis.

This pilot study is designed to evaluate a new co-designed mobile app that delivers cognitive behavioural therapy (CBT) for people with functional dyspepsia (FD), a common upper gastrointestinal disorder. The study will explore whether the app is easy to use, liked by patients, and if it helps to reduce symptoms and improve quality of life. Participants will be randomly assigned to one of three groups: 1) Mobile CBT App for 7 weeks, 2) Zoom CBT for 7 weeks, or 3) Waitlist Control (care as usual) for 7 weeks. Researchers will collect data on adherence to the app, how often participants use the app, and their feedback on using it. They will also measure changes in symptoms, quality of life, and mental health using questionnaires. Additionally, participants will undergo a baseline body surface gastric mapping test to explore if different stomach patterns affect how they respond to the CBT interventions.